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MicroRNAs (miRNAs) are an emerging class of gene expression modulators with relevant roles in several biological
processes, including cell differentiation, development, apoptosis, and regulation of the cell cycle. Deregulation of
those tiny RNA molecules has been described frequently as a major determinant for the initiation and progression
of diseases, including cancer. Not only miRNAs but also the enzymes responsible for miRNA processing could be
deregulated in cancer. In this review, we address the role of miRNAs in the pathogenesis of breast cancer, since
there are oncogenic, tumor-suppressive, and metastatic-influencing miRNAs. Additionally, the different detection
platforms and normalization strategies for miRNAs will be discussed. The major part of this review, however, will
focus on the capability of miRNAs to act as diagnostic, predictive, or prognostic biomarkers. We will give an
overview of their potential to correlate with response to or benefit from a given treatment and we will consider
their ability to give information on prognosis in breast cancer. We will focus on miRNAs validated by more than
one study or verified in independent cohorts or where results rely on preclinical as well as clinical evidence. As
such, we will discuss their potential use in the personalized management of breast cancer.Introduction
Breast cancer and breast cancer heterogeneity
Breast cancer is the most frequent carcinoma and sec-
ond most common cause of cancer-related mortality in
women [1]. Its heterogeneous character is reflected in
the classification into four intrinsic subtypes (luminal A,
luminal B, basal-like, and ErbB2+), a normal-like group,
and a new subtype, referred to as claudin-low. Histologi-
cally, breast cancer can be divided into in situ and inva-
sive carcinoma, both of which can be further subdivided
into ductal and lobular. Stratification by integrative
clustering is based on genomic and transcriptomic data
[2]. Curtis and colleagues [2] revealed new biological
subgroups as integrative clusters, characterized by well-
defined copy number alterations, gene expression, and
distinct clinical outcomes.* Correspondence: eleni.vanschooneveld@gmail.com
1Department of Oncology, University Hospitals Leuven and Catholic
University Leuven, Herestraat 49, Leuven B-3000, Belgium
Full list of author information is available at the end of the article
© 2015 van Schooneveld et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.MicroRNAs
MicroRNAs (miRNAs) are a group of small non-coding
RNAs able to regulate gene expression at the post-
transcriptional level by binding to the 3′ untranslated
region (UTR) of target mRNAs. This leads to cleavage of
the target mRNA by the Ago2 ribonuclease in the RNA-
induced silencing complex (RISC) or inhibition of trans-
lation [3]. Alternatively, miRNAs can exert their effect
by modulating the relationship between effector and tar-
get mRNAs rather than acting as regulators of particular
mRNAs [4]. Deregulation of miRNA expression and
potential altered gene expression may contribute to the
development of cancerous phenotypes [5]. Several stud-
ies showed a differential miRNA expression profile in
cancer as compared with normal, and a global miRNA
downregulation was a common trait of human malig-
nancies [6,7].Materials and methods
Relevant published articles were searched on PubMed
databases from 2001 to present by using the followingd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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RNA* or miR*) AND (breast cancer); depending on the
chapter discussed in the review, we complemented this
with AND (diagnostic OR prognostic OR predictive).
We focused on recent publications or findings vali-
dated by several independent studies. Studies were con-
sidered eligible on the basis of the following inclusion
criteria: (i) miRNAs were evaluated in breast cancer cells
or samples (blood or tissue) derived from patients with
breast cancer, including publically available breast cancer
cohorts; (ii) the relationship between the studied miR-
NAs and breast cancer biology was investigated, or (iii)
the relationship between miRNAs and outcome or ther-
apy response in breast cancer was examined. Articles
were excluded if they met one of the following criteria:
(i) published articles were retracted articles or comments;
(ii) lack of key information on breast cancer biology, prog-
nosis, or prediction of therapy response; and (iii) manu-
scripts reported on cancer types other than breast cancer.
MicroRNAs and breast cancer
The role of microRNAs in breast cancer biology and
metastasis
In cancer, miRNAs play a role in oncogenesis, metastasis,
and resistance to various therapies and can be classified as
oncogenes (oncomirs) or tumor-suppressor genes [8-10].
Additionally, both pro-metastatic (‘metastamiRs’) and
metastasis-suppressor miRNAs can be identified [11,12].
Many miRNA genes are located in genomic regions
involved in chromosomal alterations. Chromosomal re-
gions encompassing oncogenic miRNAs may be ampli-
fied, resulting in increased expression of the oncomir.
Tumor-suppressive miRNAs could reside in fragile sites
characterized by deletions or mutations, leading to re-
duced levels of these miRNAs [13,14]. An overview ofTable 1 List of major oncogenic microRNAs in breast cancer
miRNA Target Function
miR-10b HOXD10 Promotes cell migration, inv
miR-21 PDCD4, HIF1A Promotes invasion, metastas
TPM1, PTEN, PDCD4 Promotes invasion
TIMP3 Promotes invasion
miR-155 SOCS1 Promotes cell growth and p
TP53INP1 Promotes proliferation
FOXO3 Promotes proliferation and s
miR-373 CD44 Promotes cell migration and
Promotes invasion and meta
miR-520c CD44 Promotes cell migration, inv
MetastamiRs are indicated in bold. aWhen applying more than one reference, we fo
samples. The other studies serve as validation and confirm the results. EMT, epithel
hypoxia-inducible factor-1α; HOXD10, homeobox D10; miRNA, microRNA; PDCD4, p
SOCS1, suppressor of cytokine signaling 1; TIMP3, metalloproteinase inhibitor 3; TMthe most prominent miRNAs involved in the pathogen-
esis of breast cancer is depicted in Tables 1 and 2.
Oncogenic microRNAs and ‘metastamiRs’
Examples of breast oncomirs are miR-10b, miR-21, miR-
155, miR-373, and miR-520c. (See Table 1 and list of
abbreviations for miRNA targets.) OncomiRs exert their
oncogenic activity by targeting tumor-suppressor genes
and activating oncogenic transcription factors [8,15].
MiR-10b targets HOXD10, thereby promoting cell mi-
gration and invasion [8,16,17]. miR-21 has been reported
to be associated with invasive and metastatic breast cancer
[18] and regulates epithelial-to-mesenchymal transition
(EMT) and HIF1A in breast cancer stem cell-like cells
[19]. It also inhibits various tumor-suppressor proteins
[20-22]. MiR-155 suppresses SOCS1 both in vivo and
in vitro [23], and upregulation results in proliferation of
MCF7 cells [24]. FOXO3 was identified as another miR-
155 target, whose inhibition leads to enhanced cell sur-
vival and tumor growth [25]. The expression of miR-373
and -520c, which target CD44, is associated with metasta-
sis, invasion, and migration [26,27].
Tumor-suppressive and metastasis-suppressive microRNAs
Tumor-suppressor miRNAs exhibit a lower expression in
cancer cells and suppress oncogene expression, thereby
controlling cellular differentiation [28]. In regard to the
global downregulation of miRNAs in cancer, it is worth
mentioning that the majority of miRNAs have a tumor-
suppressive function, some of which exhibit anti-metastatic
properties as well. (See Table 2 and list of abbreviations for
miRNA targets).
MiR-125b, which targets erythropoietin (EPO) and its
receptor (EPOR) as well as ERBB2, is found to be one of
the most downregulated miRNAs in breast cancer [29-31].Number of samplesa Reference
asion and metastasis n = 23 [8,16,17]
is, migration and EMT Cell culture study [18,19,22]
n = 17 [20]
n = 32 [21]
roliferation n = 15 [23]
Cell culture study [24]
urvival n = 115 [25]
invasion n = 11 [26]
stasis Cell culture study [27]
asion and metastasis n = 11 [26]
cused on the study with the most relevant number of investigated patient
ial-to-mesenchymal transition; FOXO3, forkhead box protein O3; HIF1A,
rogrammed cell death protein 4; PTEN, phosphatase and tensin homolog;
1, tropomyosine 1; TP53INP, tumor protein p53 inducible nuclear protein.
Table 2 List of major tumor suppressive microRNAs in breast cancer
miRNA Target Function Number of samplesa Reference
miR-125b EPO, EPOR Inhibits cell proliferation and differentiation n = 42 [29]
ENPEP, CK2-α,CCNJ, MEGF9 Inhibits cell proliferation n = 25 [30]
ERBB2 Inhibits migration and invasion Cell line study [31]
miR-205 HMGB3 Suppresses proliferation and invasion n = 20 [32,33]
miR-17-92 Mekk2 Promotes NK cell antitumoral activity and reduces metastasis n = 20 [34,35]
miR-206 Cyclin D2, Cx43 Reduces migration, invasion and metastasis n = 128 [36,37]
miR-200 ZEB1/2, SNAI1/2 Reduces tumor growth, metastasis and EMT n = 70 [38-40]
miR-146b NFkB, STAT3 Reduces survival and metastasis n = 91 [41,42]
miR-126 IGFBP2, MERTK,PITPNC1 Reduces metastasis and angiogenesis n = 117, n = 295 [43]
No specific targets listed Reduces tumorigenesis and metastasis Cell line study [44]
miR-335 SOX4, TNC Suppresses metastasis and migration n = 20 [44,45]
miR-31 RhoA Inhibits several steps of the invasion-metastasis
cascade in breast cancer
n = 54 [46]
WAVE3, RhoA Reduces cancer progression and metastasis Cell line study [47]
WAVE3 Reduces cancer progression and metastasis n = 19 [48]
Metastasis-suppressive miRs are indicated in bold. aWhen applying more than one reference, we focused on the study with the most relevant number of
investigated patient samples. The other studies serve as validation and confirm the results. CCNJ, cyclin J; CK2-α, casein kinase 2-alpha; Cx43, connexin 43; ENPEP,
glutamylaminopeptidase or aminopeptidase A; EPO, erythropoietin; EPOR, erythropoietin receptor; ERBB2, Receptor tyrosine-protein kinase erbB-2 (human epidermal
growth factor receptor 2); HMGB3, high-mobility group box 3 gene; IGFBP2, insulin-like growth factor-binding protein 2; MEGF9, multiple EGF-like domains 9; Mekk2,
mitogen-activated protein kinase kinase kinase 2; MERTK, c-Mer tyrosine kinase; miRNA, microRNA; NFkB, nuclear factor kappa B; NK, natural killer; PITPNC1,
phosphatidylinositol transfer protein, cytoplasmic 1; RhoA, Ras homolog gene family; SNAI1/2, snail family zinc finger 1/2; SOX4, SRY-related HMG-box 4; STAT3, signal
transducer and activator of transcription 3; TNC, tenascin C; WAVE3, WAS protein family, member 3; ZEB1/2, zinc finger E-box binding homeobox 1/2.
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significantly inhibits cell proliferation and promotes
apoptosis in breast cancer [32,33]. Jiang and colleagues
[34] revealed how expression of the miR-17-92 cluster
in triple-negative breast cancer (TNBC) was associated
with significantly reduced metastasis [35]. miR-206 in-
hibits cell proliferation, migration, and invasion by target-
ing cyclin D2 and Cx43 [36,37].
Certain tumor-suppressive miRNAs have an inhibitory
role in the metastasis cascade. For example, the miR-200
family regulates EMT via E-cadherin expression by tar-
geting several EMT inducers [38-40]. MiR-146b inhibits
nuclear factor kappa B (NF-κB)-dependent interleukin
(IL)-6 expression, which is associated with impaired sur-
vival and metastasis of cancer cells [41,42]. Decreased
expression of miR-126 was seen in a variety of human
cancers, and restoration of expression reduced meta-
static endothelial recruitment and angiogenesis [43,44].
MiR-335 is known to target several metastasis-associated
genes (for example, SOX4 and TNC) [44,45]. Finally, inde-
pendent studies have reported the pleiotropic actions of
miR-31 on breast cancer metastasis and its ability to sup-
press multiple steps of the invasion-metastasis cascade, by
targeting RhoA and WAVE3 [46-48].
Context-dependent microRNAs
The action of certain miRNAs is dependent upon cellular
or environmental context and results in both tumor-
suppressive and -promoting roles [17,49]. This could inpart explain possible inconsistent outcomes from distinct
miRNA-examining studies.
As described above, miR-146 exerts its tumor-suppressive
action through negative regulation of NF-κB signaling
[41]. However, an additional target is the pro-apoptotic
DNA repair enzyme BRCA1 [50]. MiR-29 stimulates me-
tastasis and EMT by suppressing the cell-adhesion mol-
ecule peroxidasin homologue but is also capable of
restraining cancer progression by targeting proliferation-
inducing oncogenes, suppressing DNA methylation of
tumor-suppressor genes, and increasing chemosensitivity
[51]. Although most data support an oncogenic function
for miR-373 and -520c [26,27], a recent study reported
this miR-family as a tumor suppressor in estrogen recep-
tor (ER)-negative breast cancer [52].
MicroRNA detection and normalization
MicroRNA detection and genome-wide approaches
Many hybridization-based miRNA detection platforms
are being described. Though low-throughput, the most
standardized method for miRNA analysis is Northern
blotting [53]. High-throughput methods for miRNA de-
tection are the oligonucleotide miRNA microarray and
real-time reverse transcription-polymerase chain reac-
tion (RT-PCR). MiRNA microarrays are capable of ana-
lyzing hundreds of miRNAs (genome wide) in a large
number of samples. Integration of the obtained miRNA
data with mRNA expression data is useful to discover
new miRNA-gene interactions [54]. RT-PCR is another
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pression or validation of data obtained from other detec-
tion platforms [55]. Other detection techniques include
bead-based flow cytometry [6] and in situ hybridization
[56]. The limitation of the above-mentioned platforms
is their restriction to known miRNA structures. Next-
generation sequencing technologies provide new approa-
ches for discovery of new and confirmation of known
miRNAs [57,58]. An overview of the most prominent
miRNA detection methods is shown in Table 3.
MicroRNA normalization
Good normalization procedures for miRNA expression
are still lacking. A normalization strategy for miRNA
quantitative RT-PCR (qRT-PCR) is the use of endogenous
controls, like reference miRNAs (for example, miR-16) or
other small non-coding RNAs (for example, small nuclear
and nucleolar RNA). However, it is recommended to use
reference molecules belonging to the same RNA class
since they possess the same physicochemical properties
[59]. This is why miR-16 would be preferable over the use
of small nucleolar and nuclear RNAs and was used in our
study to normalize quantitative PCR data obtained from
miRNA expression analysis in blood [60]. Also, the
quantification accuracy increases by use of more than
one reference gene [59]. Another example of a potential
reliable reference gene is miR-484, whose reference-
gene utility may be enhanced by averaging with other
potential breast cancer housekeeping miRNAs (for ex-
ample, miR-330-3p, -4327, and -1271) [4]. Other nor-
malization strategies for miRNA expression include the
mean expression value strategy, as proposed by Mestdagh
and colleagues [61].
MicroRNAs as diagnostic, predictive, and
prognostic biomarkers
The ideal biomarker should be easily accessible, sensitive
enough to detect all tumors, and specific and therefore
not detectable in healthy individuals. Because of their
high tissue-specificity, great stability, and aberrant ex-
pression in different tumor types, miRNAs are thoughtTable 3 The most prominent microRNA detection methods
Detection method Throughput Sensitivity Specificity Reference
Northern blotting Low Low High [53]
Microarray High Low Low [54]
Bead-based
flow cytometry
High Medium High [6]
qRT-PCR High High High [55]
In situ hybridization Low Low Low [56]
Next-generation
sequencing
High High High [57,58]
qRT-PCR, quantitative real-time polymerase chain reaction.of as specific biomarkers with diagnostic, predictive, and
prognostic potential (Figure 1).
MicroRNAs as diagnostic biomarkers for breast cancer
heterogeneity
Early diagnosis of breast cancer
Early diagnosis is of utmost importance to reduce the
mortality rate in cancer. Therefore, the search for new
diagnostic biomarkers remains a persisting quest. The
main examined diagnostic miRNA signatures will be dis-
cussed, with a focus on those miRNAs validated by more
than one study or verified in different cohorts or both.
(For a detailed overview of the individual miRNAs, see
Table 4).
In a recent study, a signature of nine circulating miR-
NAs was capable of discriminating between early-stage
breast cancer and healthy controls [62]. A meta-analysis
concerning miR-155 showed highly sensitive and specific
diagnostic accuracy [63]. By comparing miRNA profiles
between serum samples from breast cancer patients and
healthy volunteers, Chan and colleagues [64] identified
four miRNAs as significant diagnostic markers. Cuk and
colleagues [65] found another four upregulated miRNAs
in plasma of patients with breast cancer, capable of
detecting stage I or II breast cancer, making them at-
tractive candidates for early breast cancer detection.
Another study reported three upregulated miRNAs and
one downregulated miRNA in patients with breast can-
cer compared with normal controls [66]. A prospective
study identified three significantly overexpressed serum
miRNAs in women who eventually developed breast can-
cer (cases) compared with breast cancer-free controls [67].
This study introduces a new perspective on the miRNA
function by describing their potential to predict increased
risk of developing breast cancer.
Breast cancer molecular subtypes and microRNAs
We have shown that microRNA expression profiles are
able to recapitulate the molecular breast cancer subtypes
by using mRNA profiling [60,68]. Molecular miRNA
signatures which distinguish between different breast
cancer subtypes were described for the first time (to the
best of our knowledge) by Blenkiron and colleagues [69]
and reviewed by Serpico and colleagues [70]. The com-
monly found molecular subtype-related miRNAs are
presented in Table 5.
Blenkiron and colleagues [69] profiled 309 miRNAs in
93 breast tumors with different molecular subtypes. The
differential miRNA expression resulted in a correct clas-
sification of basal versus luminal subtypes. An identified
31-miRNA signature was able to distinguish the different
breast cancer subtypes. de Rinaldis and colleagues [71]
found consistent results by revealing a 46-miRNA signa-
ture able to differentiate between breast cancer subtypes
Figure 1 Illustration of the application of microRNAs (miRNAs) as novel diagnostic, predictive, and prognostic biomarkers in breast
cancer management.
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observed by Dvigne and colleagues [4], and the common
miRNA signatures for molecular breast cancer subtypes
are listed in Table 5.
In another study, 453 miRNAs in 29 early-stage breast
cancer tumors were profiled, identifying signatures that
accurately predict ER, progesterone receptor (PR), and
HER2 status (Table 6) [72]. miR-342 showed the highest
expression in ER-positive and HER2/neu-positive lu-
minal B tumors, which was verified in recent studies
[73,74], and showed a decreased expression in TNBC.
MiR-520 g was downregulated in ER- and PR-positive
tumors.
Breast cancer histological subtypes and microRNAs
Little is known about the correlation of histological sub-
types and specific miRNA expression patterns and it is
definitely worthwhile to further investigate this relation
in the future.
Volinia and colleagues [75] found a nine-miR invasive-
ness signature by profiling miRNAs in ductal carcinoma
in situ and invasive ductal carcinoma (IDC). Giricz and
colleagues [76] revealed six differentially expressed miR-
NAs during progression from lobular carcinoma in situ
to invasive lobular carcinoma. Van der Auwera and
colleagues [77] showed a differential expression of 13 miR-
NAs in inflammatory breast cancer (IBC) versus non-IBC.Another study examined the miRNA expression profile in
IBC and found five miRNAs able to accurately classify
between IBC and non-IBC [78].
Predictive microRNAs
Predictors help to individualize therapy and diagnosis of
breast cancer, correlate with response to a given treat-
ment, and determine the treatment benefit. Recently,
several miRNAs have been described to serve as putative
therapeutic targets. (See Table 7 for described miRNAs
and Additional file 1: Table SI 1 for a more extensive
overview of predictive miRNAs).
MicroRNAs associated with hormone therapies
MiRNAs appear to be involved in the process of endo-
crine resistance [79], and research has been conducted
to identify miRNAs associated with clinical benefit of
hormone therapies.
miR-375 miR-375 demonstrated its sensitizing effect on
tamoxifen response via direct targeting of metadherin
(MTDH). Loss of MTDH restored sensitivity to tamoxi-
fen and correlated with disease-free survival (DFS) in
tamoxifen-treated patients [80].
miR-342 He and colleagues [74] found that miR-342
expression positively correlates with ERα expression and
Table 4 List of major diagnostic microRNA signatures for the early diagnosis of breast cancer
miR signature Expression (BC vs normal) Sample type Number of samples:
BC (normal)
Validation Reference
miR-15a Upregulated Serum n = 48 (24) n = 60 (51) [62]
miR-18a Upregulated Serum n = 48 (24) n = 60 (51) [62]
miR-107 Upregulated Serum n = 48 (24) n = 60 (51) [62]
miR-425 Upregulated Serum n = 48 (24) n = 60 (51) [62]
miR-133a Downregulated Serum n = 48 (24) n = 60 (51) [62]
miR-139-5p Downregulated Serum n = 48 (24) n = 60 (51) [62]
miR-143 Downregulated Serum n = 48 (24) n = 60 (51) [62]
miR-145 Downregulated Serum n = 48 (24) n = 60 (51) [62]
miR-365 Downregulated Serum n = 48 (24) n = 60 (51) [62]
miR-155 Upregulated Serum n = 184 (75) Meta-analysis (inclusion
of 3 studies)
[63]
miR-1 Upregulated Serum n = 32 (22) n = 132 (101) [64]
miR-133a Upregulated Serum n = 32 (22) n = 132 (101) [64]
miR-133b Upregulated Serum n = 32 (22) n = 132 (101) [64]
miR-92a Upregulated Serum n = 32 (22) n = 132 (101) [64]
miR-148b Upregulated Plasma n = 127 (80) n = 207 (80) [65]
miR-376c Upregulated Plasma n = 127 (80) n = 207 (80) [65]
miR-409-3p Upregulated Plasma n = 127 (80) n = 207 (80) [65]
miR-801 Upregulated Plasma n = 127 (80) n = 207 (80) [65]
miR-16 Upregulated Plasma & tissue n = 15 (15) n = 170 (100)a [66]
miR-21 Upregulated Plasma & tissue n = 15 (15) n = 170 (100)a [66]
miR-451 Upregulated Plasma & tissue n = 15 (15) n = 170 (100)a [66]
miR-145 Downregulated Plasma & tissue n = 15 (15) n = 170 (100)a [66]
miR-18a Overexpressed in cases compared to controlsb Serum n = 205 (205) n = 5 (5) [67]
miR-181a Overexpressed in cases compared to controlsb Serum n = 205 (205) n = 5 (5) [67]
miR-222 Overexpressed in cases compared to controlsb Serum n = 205 (205) n = 5 (5) [67]
Common microRNAs (miRNAs) are indicated in bold. amiRs only detected in plasma, not in tissue. bCases, women who developed breast cancer (BC); controls,
women who stayed BC-free.
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cancer cell lines enhanced sensitivity to tamoxifen-induced
apoptosis. Cittelly and colleagues [81] verified these find-
ings and reported miR-342 downregulation to be associ-
ated with tamoxifen resistance.Table 5 Common subtype-specific microRNAs found by
meta-analysis of three independent studies
Luminal A Basal HER2 Normal-like
let-7c miR-18a miR-142-3p miR-145
miR-10a miR-135b miR-150 miR-99a
let-7f miR-93 miR-100
miR-155 miR-130a
Common subtype-specific microRNAs (miRNAs)a derived from analysis by
Dvinge et al. [4] (2013), Blenkiron et al. [69] (2007), and de Rinaldis et al. [71]
(2013). aNo common miRNAs for the luminal B subtype could be found.miR-221/222 The miR-221/222 cluster is an inhibitor
of ERα and is being associated with tamoxifen resistance
in breast cancer cells [82-84]. This miRNA cluster has
also been involved in resistance to fulvestrant, a selective
ER downregulator [85].
Let-7f Aromatase inhibitors are used in endocrine ther-
apy since they decrease estrogen production by blocking
the aromatase gene CYP19A1, a direct target of let-7 f.
MiRNA expression profiling before and after treatment
with letrozole showed an increase in let-7f in preclinical
as well as clinical settings [86].
MicroRNAs associated with targeted therapies
miR-210 Jung and colleagues [87] examined the plasma
miR-210 expression level in patients with HER2+ breast
cancer before (that is, baseline expression) and after
Table 6 MicroRNA signatures for estrogen receptor,
progesterone receptor, and HER2/neu receptor status in
breast cancer
miRNA Median accuracy,
percentage
Increased miRNA expression
gives higher probability of:
ER status
miR-342 83.3 ER (+) status
miR-299-3p 100 ER (−) status
miR-217 100 ER (+) status
miR-190 100 ER (−) status
miR-135b 100 ER (-) status
miR-218 100 ER (+) status
PR status
miR-520 g 83.3 PR (−) status
miR-377 83.3 PR (+) status
miR-527-518a 100 PR (−) status
miR-520f-520c 100 PR (+) status
HER2/neu status
miR-520d 100 HER2/neu (+) status
miR-181c 100 HER2/neu (−) status
miR-302c 100 Weak response
miR-376b 100 HER2/neu (+) status
miR-30e-3p 100 Weak response
Lowery et al. [72] (2009). ER, estrogen receptor; miRNA, microRNA; PR,
progesterone receptor.
Table 7 Predictive microRNAs - microRNAs involved in respon
therapeutic strategies
Therapy Generic name miRNA Role in responsea
Hormone therapy
SERM Tamoxifen miR-375 Sensitivity
miR-342 Sensitivity
Sensitivity
miR-221/222 Resistance
SERD Fulvestrant miR-221/222 Resistance
AI Letrozole let-7f Sensitivity
Targeted therapy
Monoclonal AB Trastuzumab miR-210 Resistance
Chemotherapy
FEC miR-125b Resistance
Resistance
Resistance
Taxol/doxo miR-30c Sensitivity
Taxol miR-21 Resistance
Radiotherapy
Radiotherapy miR-34a Sensitivity
aMicroRNA (miRNA) overexpression leads to an increase in resistance or sensitivity t
AB, antibody; AI, aromatase inhibitor; BC, breast cancer; Doxo, doxorubicin; FEC, fluo
downregulator; SERM, selective estrogen receptor modulator; Taxol, paclitaxel.
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tuzumab. MiR-210 was the only miRNA with a sig-
nificant upregulated baseline expression in the residual
disease group before treatment. Therefore, high miR-210
baseline expression was associated with resistance to
trastuzumab-included chemotherapy. Results were valida-
ted by comparing miR-210 expression in trastuzumab-
sensitive and -resistant breast cancer cells and in an
independent set of pre- and post-operative plasma
samples. A significantly higher miR-210 level was found in
the trastuzumab-resistant cells and in the independent
patient cohort before surgery.
MicroRNAs associated with response to chemotherapeutic
agents
Drug sensitivity varies with each patient, making predic-
tors of benefit or resistance toward proposed chemothera-
peutic agents essential. In this way, the proportion of
patients with a beneficial treatment would increase and
toxicity of ineffective treatments would be avoided.
miR-125b Zhou and colleagues [88] reported resistance
to various chemotherapies induced by miR-125b targeted
repression of Bak1 (BCL2 antagonist killer 1), which was
verified by the clinical findings of Wang and colleagues
[89], who reported higher miR-125b expression in non-
responsive patients after admission of 5-fluorouracil.
Climent and colleagues [90] reported miR-125b deletionse (sensitivity/resistance) to conventional breast cancer
Evidence Number of patients or type of cells Reference
Preclinical/clinical 2 BC datasets [80]
Preclinical MCF-7 [74]
Clinical n = 791 [81]
Preclinical MCF-7, T47D, MM-468 [82-84]
Preclinical MCF-7 [85]
Preclinical/clinical n = 23 [86]
Preclinical/clinical n = 43 [87]
Preclinical/clinical n = 56 [89]
Preclinical MM-435, SKBR3 [88]
Clinical n = 185 [90]
Preclinical T47D, MCF-7, MM-231 [91,92]
Preclinical MM-468 [9,93]
Preclinical T47D, MCF-7, MM-231 [95,96]
o the mentioned therapy (referred to as ‘resistance’ or ‘sensitivity’, respectively).
rouracil, epirubucin and cyclophosphamide; SERD, selective estrogen receptor
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anthracycline-based chemotherapy and low recurrence
rate in patients with lymph node-negative breast cancer.
miR-30c Bockhorn and colleagues [91] described how
increased levels of miR-30c sensitized the drug response
of breast cancer cell lines to paclitaxel and doxorubicin,
and this was also seen in the preclinical model by Fang
and colleagues [92].
miR-21 Mei and colleagues [93] reported miR-21 upregu-
lation to be associated with taxol resistance in breast can-
cer cells. These results were validated in a recent study, in
which miR-21 upregulation resulted in an increase of
the anti-apoptosis protein BCL-2 and chemoresistance
in breast cancer cells [9]. The increase of BCL-2 expres-
sion was induced by direct targeting by miR-21, which
was able to unconventionally upregulate the expression
of its direct target by binding to its 3′ UTR [94].
MicroRNAs associated with radiotherapy
miR-34a Low levels of miR-34a rendered breast cancer
cells more resistant to radiotherapy [95]. These findings
were verified by Stankevicins and colleagues [96], who
postulated that miR-34a was involved in breast cell re-
sponses to low-dose X radiation. Moreover, miR-34a was
found to be upregulated by p53 in response to radiation
in normal and breast cancer cell lines [96].
Prognostic microRNAs
Since patients at higher risk might acquire differential
therapeutic interventions, the search for prognostic bio-
markers remains a continuous work in progress. Several
gene-expression studies have identified new or improved
miRNA prognostic markers, giving information on theTable 8 List of positive prognostic microRNA signatures in br
miRNAs associated with positive outcome
miRNA Case cohort
Detection Cells of origin Number o
let-7b LNA-ISH Early invasive BC 1,432
LNA-ISH Heterogeneous BC 80
miR-205 LNA-ISH Ductal BC 1,475
qRT-PCR Heterogeneous BC 84
miR-375 Solexa deep sequencing Stage II-III BC 42
miR-30a miRNA microarray IDC 221
qRT-PCR Heterogeneous BC 96
miR-342-5p miRNA microarray Heterogeneous BC 101
miR-497 qRT-PCR Heterogeneous BC 128
qRT-PCR IDC 48
BC, breast cancer; IDC, invasive ductal carcinoma; LNA-ISH, Locked Nucleic Acid-in s
real-time polymerase chain reaction.course and outcome of disease in different subgroups of
patients. To narrow this extensive area, we will emphasize
those prognostic miRNAs that are being validated (that is,
examined in more than one study or tested in the same
study) but verified in more than one cohort or dataset. An
overview of the miRNAs described in this review can be
found in Table 8 and Table 9; for a more extensive list, see
Additional file 1: Tables S2A and S2B.
MicroRNAs associated with positive prognosis
Let-7b and miR-205 Quesne and colleagues [97] re-
vealed association of let-7b and miR-205 with prognosis in
breast cancer. They applied in situ hybridization to study
miRNA expression in a population-based breast tumor
cohort and validated their findings by use of qRT-PCR.
Deregulation of let-7b, which targets the oncogenes H-
RAS and HMGA2, often occurs early in breast cancer pro-
gression and its expression is known to be downregulated
during EMT and associated with less aggressive tumors
[69,98-100]. Within luminal breast cancer, increased
let-7b expression was positively associated with survival.
Additionally, the authors reported miR-205 as another
miRNA with positive prognostic value [97]. MiR-205
regulates EMT by inhibiting E-cadherin suppression.
MiR-205 expression is associated with tumors of ductal
morphology and independently predicts survival within
this tumor subtype.
Two independent studies verified these results. Ma
and colleagues [101] showed how low let-7b expression
levels in a heterogeneous breast cancer cohort associated
with poor prognosis reflected in lower overall survival
(OS) and relapse-free survival (RFS) times. Markou and
colleagues [102] detected miRNA-205 levels in a hetero-
geneous breast cancer cohort and demonstrated how
downregulation was associated with longer DFS.east cancer
Validation cohort Reference
f samples Technique Number of samples
qRT-PCR 40 [97]
NR NR [101]
qRT-PCR 40 [97]
NR NR [102]
qRT-PCR 26 [57]
NR NR [104]
NR NR [108]
miRNA microarray 1,302 [109]
NR NR [111]
NR NR [110]
itu hybridization; miRNA, microRNA; NR, not reported; qRT-PCR, quantitative
Table 9 List of negative prognostic microRNA signatures in breast cancer
miRNAs associated with negative outcome
miRNA Case cohort Validation cohort Reference
Detection Cells of origin Number of samples Technique Number of samples
miR-122 Deep sequencing Heterogeneous BC 42 qRT-PCR 26 [57]
miR-27b-3p qRT-PCR TNBC 58 qRT-PCR 41 [113]
miR-21 qRT-PCR IDC 109 NR NR [115]
qRT-PCR Heterogeneous BC 84 NR NR [102]
miR-210 Deep sequencing IDC 118 NR NR [75]
Meta-analysis NR 699 Meta-analysis Meta-analysis [116]
Meta-analysis NR 1,809 Meta-analysis Meta-analysis [117]
miR-9 miRNA microarray ER+ BC 16 qRT-PCR 52 [120]
miR-187 LNA miRCURY LN+ BC 117 LNA miR probe 470 [121]
miR-155 qRT-PCR Heterogeneous BC 88 NR NR [122]
qRT-PCR Heterogeneous BC 231 NR NR [123]
BC, breast cancer; ER, estrogen receptor; IDC, invasive ductal carcinoma; LN, lymph node; LNA, Locked Nucleic Acid; miRNA, microRNA; NR, not reported; qRT-PCR,
quantitative real-time polymerase chain reaction; TNBC, triple-negative breast cancer.
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cing methods on blood of patients with primary stage II
or III breast cancer to indicate the miR-375 prognostic
value and validated these findings in an independent
cohort by using qRT-PCR. miR-375 is known to inhibit
migration and invasion which is partially carried out by
targeting JAK2 [103]. A differential expression exists
between patients with and without metastatic relapse.
Higher circulating levels reflect more favorable clinical
outcome in terms of pathologic complete response to
NCT and absence of relapse [57].miR-30a The prognostic features of miR-30a were in-
vestigated in 221 patients with IDC [104], showing that
miR-30a, which has been implicated in regulation of
several biological processes [105-107], negatively regu-
lates vimentin expression and overexpression suppresses
migration and invasiveness [104]. Reduced expression is
associated with unfavorable outcome (decreased RFS
and DFS). The prognostic value of miR-30a was also ex-
amined by Zhang and colleagues [108] on a heteroge-
neous set of 96 patients with breast cancer. The authors
attributed the tumor-suppressive nature of this miRNA
to its ability to target MTDH, thereby suppressing breast
tumor growth and metastasis. Decreased expression of
miR-30a was associated with an unfavorable outcome in
terms of metastasis development [108].miR-342-5p miR-342-5p has a role in cell cycle progres-
sion and cell growth regulation. The latest research by
Leivonen and colleagues [109] demonstrated how higher
expression of miR-342-5p, which is an efficient negative
regulator of the HER2 pathway, was significantly associatedwith better survival in two heterogeneous breast can-
cer cohorts.
miR-497 miR-497 is a tumor-suppressive miRNA and
its biological role is found in the regulation of the nervous
system. Several studies examined miR-497 and found its
expression to be significantly decreased in breast cancer
compared with normal breast and negatively correlated
with adverse clinicopathological characteristics. Shen and
colleagues [110] reported how elevated miR-497 expres-
sion rendered IDC patients with better prognosis. An
independent study verified its prognostic role in a
population-based breast cancer cohort, in which higher
expression was correlated with a better 5-year DFS and
OS [111].
MicroRNAs associated with negative prognosis
miR-122 Wu and colleagues [57] identified circulating
miR-122 in a heterogeneous breast cancer exploration
and validation cohort, by sequencing and RT-PCR, re-
spectively. They found miR-122 to be associated with
outcome in terms of relapse and identified a distinct ex-
pression in patients undergoing metastatic relapse and
those who remained relapse-free.
miR-27b-3p The miR-27 family is known to regulate
cell cycle progression and survival by targeting the
tumor-suppressive FOXO1 gene and is highly expressed
in breast cancer [112]. In a recent study, Shen and col-
leagues [113] aimed to identify and validate a prognostic
signature for patients with TNBC (n = 58) and found
that lymph node status and miR-27b-3p were independ-
ent predictors of poor prognosis in terms of distant
van Schooneveld et al. Breast Cancer Research  (2015) 17:21 Page 10 of 15metastasis-free survival. This result was validated in a
TNBC cohort (n = 41) [113].
miR-21 miR-21, which has its biological role in develop-
ment, morphogenesis, and differentiation, is known to
be overexpressed in breast cancer [114]. The significance
of this miRNA as a prognostic factor was examined in
two independent studies. Lee and colleagues [115] found
significantly higher expressions in IDC compared with
normal breast tissue, which positively associated with
tumor size, stage, grade, and Ki-67 expression. A higher
miR-21 expression also correlated with ER negativity
and HER2 positivity. A lower OS could be noticed in
patients with higher miR-21 expression levels [115]. In a
more recent study, miR-21 was found to inversely cor-
relate with DFS [102].
miR-210 Volinia and colleagues [75] used deep sequen-
cing to determine miR-210 in patients with IDC. miR-210
showed association with time to metastasis and OS by
uni- and multivariate analyses. Various breast cancer
genes—such as BRCA1, E-cadherin, PARP1, and RB1—
with an antagonistic behavior to miR-210 were identified.
More recently, systematic reviews and meta-analyses of
previous clinical research were performed to recapitulate
the significance of increased miR-210 in the prognosis of
cancer. Summarizing nine published studies, the authors
found that miR-210 could predict outcome, especially in
patients with breast cancer, and that miR-210 overexpres-
sion predicts DFS and RFS [116,117].
miR-9 The functional significance of miR-9 is evidenced
by its regulative role in neurogenesis, development, and
apoptosis. Dysregulation of miR-9 influences prolifera-
tion or metastasis formation and has been reported in
cancer [118]. In breast cancer, upregulation of miR-9
suppresses E-cadherin, leading to increased cell motility
and invasiveness [119]. Zhou and colleagues [120] found
miR-9 to discriminate between cases with and without
local recurrence (LR), in which the latter group showed
a significantly lower expression. In ER+ cases, a lower
10-year LR-free survival was seen in patients with high
miR-9 expression by using miRNA arrays [120].
miR-187 Using an in silico method in two independent
breast cancer cohorts, Mulrane and colleagues [121]
identified and validated miRNA-187 as being involved in
breast cancer progression. miR-187 is independently asso-
ciated with poor outcome in breast cancer (particularly,
lymph node-positive samples) in terms of reduced breast
cancer-specific survival.
miR-155 Several studies demonstrated the involvement
of miR-155 in biological processes, such as cell survival,growth, migration, and invasion [23,25]. Song and
colleagues [122] found a significantly higher miR-155
expression in formalin-fixed paraffin-embedded tumor
compared with normal tissues. Multivariate analysis
showed an inverse (yet insignificant) correlation with
breast cancer outcome in terms of OS. Recently, Kong
and colleagues [123] verified these findings and reported
miR-155 to be frequently upregulated in various types of
cancer where it plays pro-angiogenic, proliferative, and
migratory roles. Moreover, they noticed miR-155 expres-
sion levels to be associated with poor prognosis in terms
of OS [123].
MicroRNA biogenesis
MiRNA biogenesis (see Figure 2 for the canonical path-
way of miRNA biogenesis) affects both the quantity and
quality of miRNAs, providing a link between biogenesis
and the diagnostic, predictive, and prognostic power of
miRNAs.
MicroRNA biogenesis and the diagnostic potential of
microRNAs
A differential expression of miRNA-processing enzymes
may result in an altered turnover of pri- and pre-
miRNAs, which may influence the biology and etiology
of cancer. We [68] and others [69] have seen that the
expression of miRNA biogenesis genes varies between
different molecular subtypes. Therefore, the hypothesis
exists that molecular changes in miRNA-processing
enzymes might be responsible for the subtype-specific
variation of miRNA profiles.
Blenkiron and colleagues [69] demonstrated how
DICER1 and AGO2 showed a significantly lower and
respectively higher expression in the more aggressive
subtypes. Higher AGO2 and DROSHA levels and lower
DICER1 levels were detected in ER-negative breast
cancers.
MicroRNA biogenesis and the predictive and prognostic
potential of microRNAs
Aside from affecting the quantity, the miRNA biogenesis
cascade may also affect the quality and function of
miRNAs. MiRNAs exert their function in collaboration
with various proteins in the RISC complex, such as the
processing enzymes AGO2, DICER1, and TARBP2. When
overexpression of a certain miRNA results in a predictive
or prognostic potential, this property could be negated by
inadequate expression of AGO2, the catalytic subunit of
RISC. Therefore, the prognostic or predictive capability of
certain miRNAs may depend on the status of particular
miRNA-processing enzymes, which may in fact explain
the discrepancy found between several studies.
The role of miRNA-processing enzymes in breast can-
cer prognosis was also examined in different studies. For
Figure 2 The microRNA biogenesis pathway. The canonical biogenesis pathway starts in the nucleus by cleavage of the pri-miRNA transcript
by the Drosha-DGCR8 microprocessor complex [128]. After nuclear processing, the resulting precursor hairpin (pre-miRNA) is transported into the
cytoplasm by Exportin-5 in complex with Ran-GTP [129]. In the cytoplasm, cleavage into an approximately 22-nucleotide duplex is achieved by
the RNase III Dicer [130] and its interactors TRBP and PACT [131,132]. To form the active RNA-induced silencing complex (RISC) that performs gene
silencing, the functional guide strand has to be separated from the passenger strand, which is degraded subsequently [133]. miRNA, microRNA.
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ated with lower metastasis and DFS rates [124]. In terms
of predictive potential, a loss of Drosha was independ-
ently associated with better response to chemotherapeu-
tic and endocrine therapy [125]. In a case-control study,
Leaderer and colleagues [126] reported how higher
methylation levels in the XPO5 promoter region were
associated with reduced risk of breast cancer. Finally,
Sung and colleagues [127] reported seven single-nucleotide
polymorphisms in miRNA biogenesis genes to be signifi-
cantly associated with breast cancer survival.
Conclusions
Over recent years, several research groups have explored
the regulatory potential of the miRNA class of small
non-coding RNAs. Differences in expression of these
miRNAs were used to explain the heterogeneity and
disease pathology of several types of cancer. Aside
from understanding the biochemical mechanisms thesemolecules have in gene regulation, we are beginning to
understand the carcinogenic mechanisms and pathways
these small molecules could influence. Due to their obvi-
ous association with carcinogenesis, and considering their
promising diagnostic and therapeutic potential, miRNAs
will steadily be investigated to discover their effect on a
patient’s disease.
Additionally, miRNAs represent a novel class of poten-
tial biomarkers for diagnosis, prediction of treatment, or
prognosis, which are essential to improve patient manage-
ment. In this review, we focused on miRNAs validated by
more than one study or where results rely on preclinical
as well as clinical evidence. However, it needs to be
emphasized that the major challenge in identifying diag-
nostic, predictive, and prognostic miRNAs still resides in
the need to firmly validate these findings in additional
independent cohorts or by additional preclinical/clinical
verification studies. Also, it is important to integrate mul-
tivariate testing since many individual identified miRNAs
van Schooneveld et al. Breast Cancer Research  (2015) 17:21 Page 12 of 15lose their significance when correcting for multiple test-
ing. One should also take into account that some incon-
sistencies can be partly attributed to differences in
subtype distribution or cells of origin. In this way, suffi-
cient experimental evidence can be obtained in order to
provide more power to the currently insufficiently strong
miRNA markers so that they could be employed in clinical
decision-making.Additional file
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